221 related articles for article (PubMed ID: 20817430)
1. Epidemiological analysis of nasopharyngeal carcinoma in the central region of Japan during the period from 1996 to 2005.
Kimura Y; Suzuki D; Tokunaga T; Takabayashi T; Yamada T; Wakisaka N; Yoshizaki T; Murata H; Miwa K; Shoujaku H; Watanabe Y; Yamada N; Ito Y; Yuta A; Takeuchi K; Hosokawa S; Mineta H; Hasegawa Y; Fujimoto Y; Nakashima T; Fujieda S
Auris Nasus Larynx; 2011 Apr; 38(2):244-9. PubMed ID: 20817430
[TBL] [Abstract][Full Text] [Related]
2. Epidemiological research into nasopharyngeal carcinoma in the Chubu region of Japan.
Takeshita H; Furukawa M; Fujieda S; Shoujaku H; Ookura T; Sakaguchi M; Ito H; Mineta H; Harada T; Matsuura H; Saito H
Auris Nasus Larynx; 1999 Jul; 26(3):277-86. PubMed ID: 10419035
[TBL] [Abstract][Full Text] [Related]
3. Prognostic implication of pretreatment titer of serum immunoglobulin A against Epstein-Barr virus capsid antigen in nasopharyngeal carcinoma patients in Sihui, Guangdong.
Ling W; Cao SM; Huang QH; Li YH; Deng MQ
Ai Zheng; 2009 Jan; 28(1):57-9. PubMed ID: 19448418
[TBL] [Abstract][Full Text] [Related]
4. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
[TBL] [Abstract][Full Text] [Related]
5. Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China.
Liu Y; Huang Q; Liu W; Liu Q; Jia W; Chang E; Chen F; Liu Z; Guo X; Mo H; Chen J; Rao D; Ye W; Cao S; Hong M
Int J Cancer; 2012 Jul; 131(2):406-16. PubMed ID: 21866545
[TBL] [Abstract][Full Text] [Related]
6. [Relationship between clinical stages of nasopharyngeal carcinoma and Epstein-Barr virus antibodies Rta/IgG, EBNA1/IgA, VCA/IgA and EA/IgA].
Cai YL; Zheng YM; Cheng JR; Wang W; Zhang YN; Wang WH; Wu YS; Zhong WM; Li J; Mo YK
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Mar; 30(3):509-11. PubMed ID: 20335122
[TBL] [Abstract][Full Text] [Related]
7. Early detection of nasopharyngeal carcinoma using IgA anti-EBNA1 + VCA-p18 serology assay.
Romdhoni AC; Wiqoyah N; Kentjono WA
Ear Nose Throat J; 2014 Mar; 93(3):112-5. PubMed ID: 24652560
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a semi-quantitative ELISA for IgA antibody against Epstein-Barr virus capsid antigen in the serological diagnosis of nasopharyngeal carcinoma.
Chen H; Chi P; Wang W; Li L; Luo Y; Fu J; Zhang L; Liu W
Int J Infect Dis; 2014 Aug; 25():110-5. PubMed ID: 24878579
[TBL] [Abstract][Full Text] [Related]
9. Chemokine CCL27 is a novel plasma biomarker for identification the nasopharyngeal carcinoma patients from the Epstein-Barr virus capsid antigen-specific IgA seropositive population.
Mao MJ; Xue N; Wang XP; Chi PD; Liu YJ; Huang Q; Dai SQ; Liu WL
BMC Cancer; 2018 Jan; 18(1):9. PubMed ID: 29295705
[TBL] [Abstract][Full Text] [Related]
10. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.
Fachiroh J; Paramita DK; Hariwiyanto B; Harijadi A; Dahlia HL; Indrasari SR; Kusumo H; Zeng YS; Schouten T; Mubarika S; Middeldorp JM
J Clin Microbiol; 2006 Apr; 44(4):1459-67. PubMed ID: 16597877
[TBL] [Abstract][Full Text] [Related]
11. [Assessment of detection assays of Epstein-Barr viral Rta-IgG, VCA-IgA, EA-IgA and Epstein-Barr viral DNA at different clinical stages in the diagnosis of nasopharyngeal carcinoma].
Luo YL; Chen H; Peng SG; Lin JH; Huang PY
Zhonghua Yi Xue Za Zhi; 2013 Nov; 93(44):3516-9. PubMed ID: 24521892
[TBL] [Abstract][Full Text] [Related]
12. Expression of VCA (viral capsid antigen) and EBNA1 (Epstein-Barr-virus-encoded nuclear antigen 1) genes of Epstein-Barr virus in Pichia pastoris and application of the products in a screening test for patients with nasopharyngeal carcinoma.
Hu B; Hong G; Li Z; Xu J; Zhu Z; Li L
Biotechnol Appl Biochem; 2007 May; 47(Pt 1):59-69. PubMed ID: 17129209
[TBL] [Abstract][Full Text] [Related]
13. Significance of plasma IgA and IgG antibodies to Epstein-Barr virus early and viral capsid antigens in Thai nasopharyngeal carcinoma.
Tiwawech D; Srivatanakul P; Karaluk A; Ishida T
Asian Pac J Cancer Prev; 2003; 4(2):113-8. PubMed ID: 12875623
[TBL] [Abstract][Full Text] [Related]
14. Titers of Epstein-Barr virus-related antibodies in nasopharyngeal carcinoma in Japan.
Tamada A; Makimoto K; Yamabe H; Imai J; Hinuma Y; Oyagi A; Araki T
Cancer; 1984 Feb; 53(3):430-40. PubMed ID: 6318948
[TBL] [Abstract][Full Text] [Related]
15. Subtype distribution and long-term titer fluctuation patterns of serum anti-Epstein-Barr virus antibodies in a non-nasopharyngeal carcinoma population from an endemic area in South China: a cohort study.
Du JL; Chen SH; Huang QH; Xie SH; Ye YF; Gao R; Guo J; Yang MJ; Liu Q; Hong MH; Cao SM
Chin J Cancer; 2016 Aug; 35(1):78. PubMed ID: 27527073
[TBL] [Abstract][Full Text] [Related]
16. Expression of EBV antibody EA-IgA, Rta-IgG and VCA-IgA and SA in serum and the implication of combined assay in nasopharyngeal carcinoma diagnosis.
Xia C; Zhu K; Zheng G
Int J Clin Exp Pathol; 2015; 8(12):16104-10. PubMed ID: 26884888
[TBL] [Abstract][Full Text] [Related]
17. EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma.
Chan KH; Gu YL; Ng F; Ng PS; Seto WH; Sham JS; Chua D; Wei W; Chen YL; Luk W; Zong YS; Ng MH
Int J Cancer; 2003 Jul; 105(5):706-9. PubMed ID: 12740922
[TBL] [Abstract][Full Text] [Related]
18. Nasopharyngeal carcinoma in Brunei Darussalam: low incidence among the Chinese and an evaluation of antibodies to Epstein-Barr virus antigens as biomarkers.
Yeo CH; Abdullah MS; Telesinghe PU; Ramasamy R
Singapore Med J; 2009 Apr; 50(4):371-7. PubMed ID: 19421680
[TBL] [Abstract][Full Text] [Related]
19. Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma.
Chang KP; Hsu CL; Chang YL; Tsang NM; Chen CK; Lee TJ; Tsao KC; Huang CG; Chang YS; Yu JS; Hao SP
Oral Oncol; 2008 Aug; 44(8):784-92. PubMed ID: 18206420
[TBL] [Abstract][Full Text] [Related]
20. Loss of heterozygosity and its correlation with clinical outcome and Epstein-Barr virus infection in nasopharyngeal carcinoma.
Shao JY; Huang XM; Yu XJ; Huang LX; Wu QL; Xia JC; Wang HY; Feng QS; Ren ZF; Ernberg I; Hu LF; Zeng YX
Anticancer Res; 2001; 21(4B):3021-9. PubMed ID: 11712805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]